STAT

SEPTEMBER 7, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.

Vaccines 266

Vaccines 266

Express Pharma

SEPTEMBER 7, 2024

The pharma and biotech sector is among the most valued segments with upward growth peaks even in turbulent economic turmoil. A sector that is directly synergistic with this segment is the CRO/CDMO industry. There are almost 100+ CDMOs in India with the addition of new start-ups every year. The CDMO industry is going to be around Rs 18,800 crore in 2024 with a CAGR of 14.67 per cent as per a recent report.

52

52

The Honest Apothecary

SEPTEMBER 7, 2024

The Honest Apothecary blog was born over 20 years ago. It grew out of my love for pharmacy, medicine, and of course…writing. For years I wrote on topics with a pharmaceutical flavor to both prescription takers and dispensers. But over time I began to outgrow the blog. Like a butterfly that could no longer be […] The post The Honest Apothecary – Reimagined first appeared on The Honest Apothecary.

52

52

PharmaTech

SEPTEMBER 7, 2024

New technologies improve efficiency and remove operator intervention.

52

52

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

Pharmacy Times

SEPTEMBER 7, 2024

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

48

48

Pharmacy Times

SEPTEMBER 7, 2024

Alessandra Ferrajoli, MD, discusses the importance of renal function for BCL2 inhibitors to avoid tumor lysis syndrome and cardiovascular history for BTK inhibitors to mitigate arrhythmia risks.

26

26